Traditionally, understanding the electrical activity within heart cells, known as intracellular signals, has been a complex and invasive process. To capture these signals, scientists would need to penetrate the cells using microelectrodes, a technique that can damage the cells and complicate large-scale studies. However, this new method allows researchers to monitor these crucial signals without physically entering the cells, thereby avoiding damage and improving the feasibility of high-throughput testing.

The breakthrough hinges on a deep understanding of the relationship between the electrical signals that occur within the cells (intracellular signals) and those that can be measured from the cell’s surface (extracellular signals). As Zeinab Jahed, a senior author of the study and professor at UC San Diego, explains, “We discovered that extracellular signals hold the information we need to unlock the intracellular features that we’re interested in.”

While extracellular signals can be detected with less invasive methods, they typically provide limited details about the inner workings of the cells. Jahed likens it to “listening to a conversation through a wall—you can detect that communication is happening, but you miss the specific details.” In contrast, intracellular signals offer rich details but are typically captured through invasive, more technically demanding methods. By using AI, the team was able to correlate these two sets of signals and reconstruct the intracellular activity with remarkable accuracy.

A Step-By-Step Look at the Research

To develop this cutting-edge method, the researchers engineered an array of nanoscale, needle-shaped electrodes made from silica coated with platinum. These electrodes, each about 200 times smaller than a single heart muscle cell, were used to capture electrical signals from heart cells grown from stem cells. The heart muscle cells were placed on the electrode array, and a vast dataset was generated by recording thousands of pairs of extracellular and intracellular signals. The dataset also included responses of the cells to various drugs, providing valuable insights into cellular behavior under different conditions.

By analyzing these signal pairs, the team identified patterns and relationships between the extracellular and intracellular signals. This dataset became the foundation for training a deep learning AI model capable of predicting intracellular signals based solely on the extracellular data. The model demonstrated high precision in reconstructing the internal electrical activity of the heart cells, even in complex drug exposure scenarios.

Transforming Drug Testing and Personalized Medicine

One of the most significant implications of this new AI-driven technique is its potential to accelerate drug development, particularly in the field of cardiotoxicity testing. Every new pharmaceutical must undergo rigorous safety testing to ensure it does not negatively impact the heart. Part of this testing involves evaluating intracellular electrical signals from heart muscle cells, as even subtle changes in these signals can indicate potential harmful effects.

Currently, cardiotoxicity testing is a costly and time-consuming process, often requiring animal models, which don’t always predict human responses accurately. With this new method, researchers can conduct drug screening directly on human heart cells, providing a more accurate and relevant picture of how a drug might affect the heart. This not only has the potential to reduce the need for animal testing but also to streamline the drug development process, cutting both time and costs.

“This could dramatically reduce the time and cost of drug development,” said Jahed. “And because the cells used in these tests are derived from human stem cells, it also opens the door to personalized medicine. Drugs could be screened on patient-specific cells to predict how an individual might respond to these treatments.”

Expanding Beyond Cardiac Research

Although the current study focuses on heart muscle cells, the team is already working to expand this AI-driven method to other types of cells, such as neurons. The ability to noninvasively monitor and analyze cellular activity in various tissues could provide unprecedented insights into a wide array of cellular processes, potentially leading to breakthroughs in understanding and treating a variety of diseases.

By applying this technology to different cell types, researchers hope to gain a deeper understanding of cellular behaviors in both healthy and diseased states, paving the way for more personalized and effective treatments across a wide spectrum of medical conditions.

Conclusion

This innovative AI-driven technique marks a significant leap forward in noninvasive cellular monitoring, particularly in the study of heart cells. With the potential to improve drug testing, reduce the need for animal models, and enable personalized medicine, this breakthrough is poised to transform the future of cardiac research and drug development. As the technology continues to evolve, the possibilities for its application across a variety of cell types and medical fields are vast, offering new hope for patients and researchers alike.

The post AI-Driven Technique Revolutionizes Monitoring of Heart Cell Activity: A Breakthrough in Noninvasive Cardiac Research appeared first on FolksTimes.

Led by the University of East Anglia (UEA), the research utilized advanced mathematical modeling and machine learning techniques, specifically Latent Process Decomposition (LPD), to analyze genetic data from osteosarcoma patients. This approach allowed the team to categorize patients into different subgroups based on their unique genetic profiles. Previously, all osteosarcoma patients were treated using a one-size-fits-all approach, leading to varied outcomes.

Osteosarcoma, which primarily affects children and teenagers, has historically been treated with a combination of chemotherapy and surgery, sometimes resulting in severe side effects, including limb amputation. Despite numerous international clinical trials investigating new treatments, progress has been slow, with many trials labeled as “failed.” However, this new research suggests that the drugs tested in those trials may have worked for specific subtypes of the cancer, which were previously overlooked.

Dr. Darrell Green, the lead author of the study from UEA’s Norwich Medical School, highlighted the significance of this finding: “Since the 1970s, osteosarcoma has been treated using untargeted chemotherapy and surgery. While this approach has led to mixed results, our study shows that certain subtypes of osteosarcoma responded to new drugs tested in clinical trials, indicating the existence of specific patient groups that may benefit from these treatments.”

Dr. Green also noted that by using this new algorithm to categorize patients, there is hope for improving clinical trial outcomes and providing more targeted treatments in the future. “This could help move away from standard chemotherapy, leading to more personalized and effective care for osteosarcoma patients.”

This research is part of an ongoing effort to find kinder, more precise treatments for osteosarcoma, an area that has received significant attention from Children with Cancer UK, which funded the study. Dr. Sultana Choudhry, Head of Research at the charity, emphasized the importance of such research, stating, “Investing in pioneering research is crucial to improving survival rates and finding better treatments for young cancer patients.”

The study also reveals that the survival rate for osteosarcoma has remained stagnant at around 50% for over 45 years. One of the main challenges has been the difficulty in fully understanding the different subtypes of the cancer and how the immune system interacts with the tumor. This lack of knowledge has hindered efforts to improve survival rates and develop more effective treatments.

Researchers have attempted to categorize osteosarcoma into distinct subtypes in the past, but earlier methods did not account for the considerable variations within individual tumors. Tumors are often composed of multiple types of cancer cells, making it difficult to predict how they will behave or respond to treatment. The LPD method used in this study addresses this issue by analyzing gene activity patterns in tumors, allowing for a more accurate understanding of the different “functional states” that make up the cancer.

This advanced technique uncovered three unique osteosarcoma subtypes, one of which was found to respond poorly to the standard chemotherapy drug combination known as MAP. By grouping patients based on these genetic patterns, doctors could make more informed decisions regarding treatment plans.

While the study has some limitations, including a small dataset and incomplete clinical data, the LPD method proved to be reliable, identifying consistent subgroups across four independent data sets. As more data becomes available, the accuracy of this machine learning tool will improve, potentially leading to better treatment outcomes for osteosarcoma patients in the future.

In summary, this groundbreaking research offers a promising new approach to diagnosing and treating osteosarcoma. By identifying distinct subtypes of the cancer, the study paves the way for more targeted and effective treatments, providing hope for children and teenagers affected by this rare and aggressive disease.

The post New Study Identifies Subtypes of Osteosarcoma, Paving the Way for Targeted Treatments appeared first on FolksTimes.